title: Lymphoproliferative diseases of the ocular adnexa in Korea.
abstract: OBJECTIVE
  To evaluate the clinical features, treatments, and outcomes of patients with ocular lymphoproliferative disease classified according to the World Health Organization classification and to determine prognostic factors of this disease in South Korea.
  
  
  METHODS
  Between March 1, 1995, and December 31, 2005, 128 cases of patients with ocular lymphoid tumors treated at the Samsung Medical Center were retrospectively reviewed.
  
  
  RESULTS
  The mean patient age was 46.3 years (range, 1-87 years). The major histopathologic subtypes were mucosa-associated lymphoid tissue (MALT) lymphoma in 96 patients (75.0%), lymphoid hyperplasia in 11 (8.6%), diffuse large B-cell lymphoma in 6 (4.7%), and mantle cell lymphoma in 4 (3.1%). Ocular lymphoproliferative lesions were located in the conjunctiva (53 patients), the eyelid (33 patients), and the orbit (42 patients). Twenty patients had tumor relapses (15.6%), and 9 died of lymphoma during follow-up (7.0%). Regarding the analysis of prognostic factors, most patients with MALT lymphoma evidenced local disease, required local treatment, and exhibited a superior prognosis.
  
  
  CONCLUSIONS
  Lymphomas of the MALT type constitute most ocular adnexal lymphoproliferative diseases and occur more frequently in South Korea than in Western countries. Patients with MALT lymphoma have favorable outcomes compared with patients with other types of lymphoma.
authors: Department of Ophthalmology, Seoul Veterans Hospital, 50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea.
authors: Dong-Eun
authors: DE
authors: Oh
authors: Yoon-Duck
authors: YD
authors: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003230:Conjunctival Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D005142:Eyelid Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D007223:Infant; D007723:Korea / Q000453:epidemiology; D018442:Lymphoma, B-Cell, Marginal Zone / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D020522:Lymphoma, Mantle-Cell / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009918:Orbital Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D019310:Pseudolymphoma / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D011878:Radiotherapy; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents